Glucocorticoid therapy for sepsis in the AI era: a survey on current and future approaches

• Published in: Computational and structural biotechnology journal 2024-12, Vol.24, p.292-305
• Main Authors: Liang, Chenglong, Pan, Shuo, Wu, Wei, Chen, Fanxuan, Zhang, Chengxi, Zhou, Chen, Gao, Yifan, Ruan, Xiangyuan, Quan, Shichao, Zhao, Qi, Pan, Jingye
• Format: Article
• Language: English
• Subjects: Artificial intelligence; Glucocorticoid therapy; Sepsis; Therapeutic strategies
• ISSN: 2001-0370; 2001-0370
• DOI: 10.1016/j.csbj.2024.04.020

Sepsis, a life-threatening medical condition, manifests as new or worsening organ failures due to a dysregulated host response to infection. Many patients with sepsis have manifested a hyperinflammatory phenotype leading to the identification of inflammatory modulation by corticosteroids as a key treatment modality. However, the optimal use of corticosteroids in sepsis treatment remains a contentious subject, necessitating a deeper understanding of their physiological and pharmacological effects. Our study conducts a comprehensive review of randomized controlled trials (RCTs) focusing on traditional corticosteroid treatment in sepsis, alongside an analysis of evolving clinical guidelines. Additionally, we explore the emerging role of artificial intelligence (AI) in medicine, particularly in diagnosing, prognosticating, and treating sepsis. AI's advanced data processing capabilities reveal new avenues for enhancing corticosteroid therapeutic strategies in sepsis. The integration of AI in sepsis treatment has the potential to address existing gaps in knowledge, especially in the application of corticosteroids. Our findings suggest that combining corticosteroid therapy with AI-driven insights could lead to more personalized and effective sepsis treatments. This approach holds promise for improving clinical outcomes and presents a significant advancement in the management of this complex and often fatal condition. [Display omitted]